ANKRD29

Across TCGA pan-cancer cohorts, ANKRD29 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKRD29 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ANKRD29 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKRD29 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, SKCM, and UCEC are the cancer types where ANKRD29 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.112	0.657	<.001	30	view →
SKCM	OS	Median	All	0.247	0.784	<.001	15	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.029	14	view →
LUAD	OS	Median	II,III,IV	0.090	0.709	<.001	12	view →
COAD	OS	Median	III,IV	0.168	0.691	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANKRD29–STAD (DFS)

Open the STAD breakdown →